Thioprine (Azathioprine) 50mg Film-Coated Tablet, 10×10’s Blister Pack

Prevent rejection of kidney transplants and treat severe rheumatoid arthritis, which does not respond to conventional treatment.

Share Now

Additional Information

DescriptionAzathioprine is an imidazole derivative of 6-mercaptopurine (6-MP). It is rapidly broken down in vivo into 6-MP and 1-methyl-4-nitro-5-thioimidazole. 6-MP readily crosses cell membranes and is converted intracellularly into a number of purine thioanalogues, which include the main active nucleotide, thioinosinic acid. The activity of the methylnitroimidazole moiety has not been defined clearly. However, in various systems it appears to modify the activity of azathioprine compared with that of 6-MP.
Active IngredientAzathioprine
IndicationAzathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basic immunosuppression). Azathioprine is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung, or pancreas transplants. Azathioprine is indicated either alone or in combination with corticosteroids and/or other drugs and procedures in severe cases of the following diseases, in patients who are intolerant to steroids or who are dependent on steroids and in whom the therapeutic response is inadequate despite treatment with high doses of steroids:

  • Severe active rheumatoid arthritis that cannot be kept under control by less toxic agents (disease modifying anti-rheumatic drugs, DMARDs).
  • Severe or moderately severe inflammatory intestinal disease (Crohn’s disease or ulcerative colitis).
  • Systemic lupus erythematosus
  • Dermatomyositis.
  • Auto-immune chronic active hepatitis.
  • Polyarteritis nodosa.
  • Refractory warm auto-immune haemolytic anaemia.
  • Chronic refractory idiopathic thrombocytopenic purpura.
Strengths50mg film-coated Tablet
Business PartnerMylan


Related Products


Pharma Solution is the marketing agent and Distributor for the listed products for the Gulf and MENA region. The products are either registered and approved by the  respective local health authority or contracted by the MAH to supply to the end users  on a named patient basis. Some products such  as Orphan drugs, rare diseases medicines are imported based on special import permits and as per need of the Hospitals in compliance with full documentation.

[elfsight_whatsapp_chat id='1']